Systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) causes parkinsonism in humans and subhuman primates, but not in rats and many other laboratory animals; mice are intermediate in their susceptibility. Since MPTP causes selective dopaminergic neurotoxicity when infused directly into rat substantia nigra, we hypothesized that systemic MPTP may be metabolized by monoamine oxidase and/or other enzymes in rat brain capillaries and possibly other peripheral organs and thus prevented from reaching its neuronal sites of toxicity. We tested this hypothesis by assessing monoamine oxidase in isolated cerebral microvessels of humans; rats, and mice by measuring the specific binding of [3H]pargyline, an irreversible monoamine oxidase inhibitor, and by estimating the rates of MPTP and benzylamine oxidation.
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[3H]Pargyline binding to rat cerebral microvessels was about 10-fold higher than to human or mouse microvessels. Also, MPTP oxidation by rat brain microvessels was about 30-fold greater than by human microvessels; mouse microvessels yielded intermediate values. These results may explain, at least in part, the marked species differences in susceptibility to systemic MPTP. They also suggest the potential importance of "enzyme barriers" at the blood-brain interface that can metabolize toxins not excluded by structural barriers, and may provide biological bases for developing therapeutic strategies for the prevention of MPTP-induced neurotoxicity and other neurotoxic conditions including, possibly, Parkinson disease.
Systemic administration of small quantities of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to humans and other primates destroys nigrostriatal dopaminergic neurons and causes an acute and irreversible parkinsonian syndrome (1) (2) (3) (4) (5) . Neurotoxicity probably results from MPTP metabolism by brain monoamine oxidase [MAO; amine:oxygen oxidoreductase (deaminating) (flavin-containing), EC 1.4.3.4 ] to 1-methyl-4-phenyl-2,3-dihydropyridinium cation (2,3-MPDP+), which is further oxidized to 1-methyl-4-phenylpyridinium (MPP+) (Fig. 1) (6) (7) (8) (9) (10) . Although selective uptake of MPP+ by dopaminergic neurons may explain the relative specificity of MPTP toxicity (11) , many of the mechanisms that underlie the toxicity remain unknown (see ref. 12 for review). A most intriguing observation is that many common laboratory animals, with the exception of the mouse (13) , are quite resistant to systemic MPTP neurotoxicity. This observation has focused our attention on the biological bases for the marked species differences in systemic MPTP neurotoxicity, which may have important heuristic and practical implications concerning not only the mechanisms of the neurotoxicity but also the pathogenesis of Parkinson disease and other human neurodegenerative disorders. Although systemic MPTP does not cause nigrostriatal abnormalities in the rat, direct infusion of MPTP into rat substantia nigra selectively destroys zona compacta dopaminergic neurons and depletes striatal dopamine and its metabolites (14, 15) . This suggests that the rat's resistance to systemic MPTP may be a property of the blood-brain barrier and other organs that can metabolize MPTP and prevent it from reaching its brain targets in sufficient concentrations. Because MPTP is a known substrate for enzymatic oxidation by MAO-B (6, 16) , and since brain capillaries possess MAO activity (17) (18) (19) (20) (21) (22) , we reasoned that MAO activity in brain microvessels from different species may correlate invrsely with their susceptibility to systemic MPTP neurotoxicity.
We examined isolated brain microvessels ofhumans, mice, and rats (examples of high susceptibility, partial sensitivity, and resistance to MPTP toxicity) for their MAO content and activity. We also studied mitochondria-enriched preparations from the cerebral cortex and liver of these three species because ofthe importance ofbrain MAO in converting MPTP to the neurotoxic MPP+, and the importance of the liver in the systemic metabolism of MPTP. We assessed MAO in these tissue preparations by assaying specific [3H]pargyline binding to MAO molecules, which is irreversible and stoichiometric (23, 24) , and by measuring the enzymatic oxidation of MPTP and benzylamine. METHODS Preparation of Tissues. Human, rat, and mouse tissues were used. Human brain and liver were sampled at autopsy from six subjects (four men and two women), aged 30 to 71 years, who had no evidence of brain or liver diseases. The time interval between death and autopsy ranged between 3 and 12 hr (mean = 8 hr). Male Wistar rats (250 g) and male COBS CF-1 mice (25 g) were purchased from Hilltop Lab Animals (Scottsdale, PA) and were killed by decapitation. Brain and liver samples were immersed in ice-cold physiological buffers. The cerebral cortical mantles were dissected free of meninges and choroid plexus before microvessel isolation. All procedures were performed at 0-40C unless otherwise stated.
Microvessels were obtained from cerebral cortical mantles by bulk isolation (25) . Each human cerebral microvessel preparation was obtained from the cerebral cortex of one individual, whereas each rat and mouse microvessel preparation was obtained from cerebral cortical mantles pooled from 5-14 animals. Microvessel purity was checked by microscopy and occasionally by biochemical assays of their enrichment with y-glutamyl transpeptidase and alkaline phosphatase (26, 27 In some experments, [3H]pargyline binding was followed by extensive washing of the tissue pellet, which was then dissolved in 5% NaDodSO4 and processed for PAGE (29) .
The gels were either sliced into 2-mm segments, and each segment was dissolved and assayed for its 3H content, or were processed for autoradiography.
Assay of MAO Activity. MAO activity was assayed by a modification of the procedure of Szutowicz et al. (30) , which is based on the colorimetric determination of the H202 formed. The reaction mixture (0.7 ml) contained 100 mM sodium phosphate buffer (pH 7.4), 3 
RESULTS
As previously reported (25) (26) (27) , microvessel preparations consisted of segments of capillaries, arterioles, and venules that ranged from 4 to 30 ,um in diameter. The vast majority were less than 10 ,m in diameter. Larger microvessels often had smooth muscles, but we estimate their contribution at <15%. y-Glutamyl transpeptidase and alkaline phosphatase activities were >20-fold higher in microvessels than in the cerebral cortex from which microvessels were obtained.
Based on the microscopic and biochemical assessment of microvessel purity, we estimate that contaminants do not exceed 5% of the preparation. findings in human, rat, and mouse cerebral microvessels. Rat microvessels (and human, rat, and mouse livers; results not shown) exhibited two distinct radioactive bands, corresponding to the apparent molecular weights of the two types of MAO (29) . No other radioactive bands were noted either in autoradiograms of these gels or in segments of gels that were subjected to scintillation counting. Human and mouse microvessels showed minimal radioactivity in the same region of the gel, but no definite bands (Fig. 3) . In the case of rat microvessels, the smaller peak closer to the origin (Mr -65,000) was abolished in the presence of clorgyline, which inhibits MAO-A at low concentrations; whereas the larger peak towards the front (Mr =58,000) was completely abolished by deprenyl, which inhibits MAO-B at low concentrations (results not shown). Both peaks were abolished when rat microvessels were preincubated with excess unlabeled for MPTP metabolism by the "enzyme barrier" at the blood-brain interface, which may prevent access of MPTP and its metabolites to their targets. The findings of low [3H]pargyline binding and of intermediate MPTP and benzylamine oxidation by brain microvessels of the mouse, a species that is partially sensitive to systemic MPTP (13), further support our hypothesis. In fact, of the three indices of MAO activity that were tested in this study (pargyline binding and MPTP and benzylamine oxidation), MPTP oxidation by brain microvessels from the three species correlated best with their known susceptibility to systemic MPTP neurotoxicity. However, it should be emphasized that a larger number of animal species need to be tested before this hypothesis can be accepted. Even then, it is our belief that MPTP neurotoxicity is a multifaceted and complex process, and therefore we must caution that our observations may explain only in part the differences among species in their susceptibility to systemic MPTP. The results also support the concept of a "chemical" blood-brain barrier (19) that complements the "physical" blood-brain barrier with its tight endothelial cell junctions and few pinocytotic vesicles, by metabolizing substances that are not excluded by the physical barrier. We also found that [3H]pargyline binding and MPTP oxidation in the rat cerebral cortex are not significantly different from that in the human cortex (Tables 1 and 2 ). This further supports previous findings (14, 15) that MPTP, when directly injected into the rat brain, can induce toxicity via its eventual conversion to MPP+ by MAO (Fig. 1) . However, the finding of low MAO in the mouse cerebral cortex (Tables 1 and 2) may offer additional possible explanation for the intermediate susceptibility of the mouse to MPTP neurotoxicity (13) . We have no good explanation for the significantly higher capacity to oxidize benzylamine by human cerebral cortex and liver preparations over those of the rat and mouse (Tables 1 and 2 ). Similarly, we do not know why benzylamine is a better substrate than MPTP for human MAO. Several methodological questions brought up by our results should be addressed. The first concerns the purity of microvessels, and the possibility that any of the results could be due to contamination of microvessels with neuronal or glial elements. This is unlikely because human cerebral cortex has higher MAO than human microvessels, and contamination would result in higher MAO in human microvessels. On the other hand, MAO in rat cerebral cortex is much lower than in rat microvessels, and contamination would result in underestimation of the high MAO activity in rat microvessels. Another concern is the cellular heterogeneity of microvessels, which in addition to endothelium, contain pericytes and a minor component of smooth muscle cells (26) . Since endothelial cells constitute the major component of microvessels, we believe that most of the MAO in rat brain microvessels is located in these cells. A third concern is the possible postmortem instability of MAO in human tissues. This was ruled out as an explanation for the low MAO in human tissues, especially microvessels, because pargyline binding and MPTP oxidation were not decreased in experiments where rats were killed and kept at room temperature for 6-8 hr before sampling of their tissues and subsequent isolation of cerebral microvessels and crude mitochondrial preparations. This is consistent with the known resistance of MAO to postmortem changes (32) .
As MPTP seems to be vigorously oxidized by rat brain microvessels, the fate of the eventual product, MPP', and the reason for its inability to reach its sites of action in the nigrostriatal system should be addressed. When MPTP and MPP+ were infused directly into the rat substantia nigra, MPTP selectively destroyed dopaminergic neurons of the pars compacta, without affecting other neurons or glia at the injection site (15) . In contradistinction, MPP+ caused indiscriminate tissue destruction at the infusion site, suggesting that it is a potent nonspecific cytotoxin (14, 15 
